

# Paradigm Biopharmaceuticals Ltd

19:26 27 May 2019

## Paradigm Biopharmaceuticals receives more positive real-world patient data

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has received real-world data from 22 more patients with knee osteoarthritis (OA) treated with injectable pentosan polysulfate (iPPS).

The total real-world patients treated with iPPS is now 205 with a recorded 51.3% reduction in pain.

The 51.3% average reduction in pain score across 205 subjects with knee OA, continues to demonstrate iPPS's superiority over the 15% pain reduction scores reported for opioid treatments for chronic pain in OA of the knee and hip.

After recently raising \$77.9 million, the company is well funded to deliver on a pipeline of potential catalysts in 2019.

READ: Paradigm Biopharmaceuticals completes retail component of \$26.3 million entitlement offer

Paradigm's CEO Paul Rennie said: "We are very pleased to see that since October 2017 and after the report of the eighth group of SAS patients there is a consistent average knee pain reduction of greater than 50% across 205 patients.

"Of important relevance to us is that Paradigm now has accumulated data on 205 patients being successfully treated with iPPS for OA associated BMLs.

"The number of patients seeking treatment via the TGA SAS is a strong feedback that the patients are receiving a clinically meaningful benefit from the iPPS treatment.

"Our strategy of obtaining real world evidence as we prepare our FDA IND submission for our Phase 3 OA trial will provide valuable data on our newly manufactured Phase 3 trial product and will assist in fine tuning our Phase 3 Trial design."

Phase 3 clinical trial product to also be used in real world

Notably, Paradigm has completed the production of its phase 3 clinical trial product

From the September quarter of this year, doctors will treat patients with the phase 3 clinical trial product under the TGA SAS.

Paradigm is aiming to achieve Fast-Track designation and begin a phase 3 trial in the US in

CY2019, both these initiatives are expected to attract significant big pharma

**Price:** 2.7

**Market Cap:** \$521.25 m

### 1 Year Share Price Graph



October 2018 April 2019 October 2019

### Share Information

**Code:** PAR

**Listing:** ASX

**52 week High Low**  
3.26 0.708041

**Sector:** Pharma & Biotech

**Website:** www.paradigmbiopharma.com

### Company Synopsis:

*Paradigm Biopharmaceuticals Ltd (ASX:PAR) is listed on the Australian Securities Exchange.*

action@proactiveinvestors.com

interest.

Bell Potter's take on speculative osteoarthritis treatment company Paradigm Biopharmaceuticals is still rather bullish, writes @myriamrobin #RearWindow #ausbiz <https://t.co/UeWmyDvIHk>

— Financial Review (@FinancialReview) May 20, 2019

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

#### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).